

TCS/16/60 – Immunoglobulin Replacement Therapy for Immunoglobulin G Subclass 2 Deficient Patients with Bronchiectasis – A Proof of Concept Study.

Bronchiectasis is a common chronic lung condition with over 1,000 patients attending secondary care in NHS Lothian. Such patients have permanent airways damage leading to daily symptoms of cough, sputum production and recurrent respiratory tract infections. We have found a severe deficiency of the immune system as a rare cause of bronchiectasis (called immunoglobulin G subclass 2 deficiency) and occurs in about 1 in 20 bronchiectasis patients. Our pilot work shows these patients have more chest infections and their lung function deteriorates more rapidly. There are no trials to date to guide doctors to decide whether we should replace this deficiency from donated blood or not. The aim with treatment is to prevent disease progression and avoid the need for long term antibiotics. This proof of concept trial will help us understand how this treatment works and its acceptability to patients. This study will help us decide whether we should pursue a future formalised randomised controlled trial in many centres throughout the UK and how we should evaluate such a treatment.